Perfuse Therapeutics Inc. has received FDA approval of its IND application for a first-in-human phase I/IIa study of PER-001 intravitreal implant in patients with glaucoma.
CSPC Pharmaceutical Group Ltd. has received FDA clearance of its IND for a phase I trial of its antibody-drug conjugate CPO-301 for the treatment of advanced lung cancer with alterations in the EGFR gene or EGFR over-expression.
Comanche Biopharma Corp. has received IND clearance from the FDA to conduct a first-in-human study of CBP-4888, its novel, small interfering ribonucleic acid (siRNA) therapy to treat pre-eclampsia.
RSS
